A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants with Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer

Protocol No

MERCK-MK-6070-002

Staff Member

Jonathan Thompson

Phase

I/II

Summary

This trial is testing MK-6070 and ifinatamab deruxtecan (I-DXd), given alone or together, in
adults with extensive-stage small cell lung cancer (ES-SCLC) that has been previously treated. MK-6070 and I-DXd are experimental and giving them together is experimental. They have not been approved to treat ES-SCLC or other types of cancer. This trial will be testing different doses and schedules of MK-6070 and I-DXd, given alone or together, to find recommended doses and schedules for additional testing in this and other clinical trials.

Objective

A Phase 1b 2 Study of MK-6070 and I-DXd in Patients with RR Extensive Stage SCLC

Status

OPEN TO ACCRUAL